J. C. C. Lorenzi

This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.

This paper isolates and characterizes nanobodies from camelids and engineered mice that neutralize SARS-CoV-2 variants through conserved epitopes and multimeric avidity.

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

This study evaluates the neutralizing activity of 9 anti-HIV-1 bNAbs against primary African isolates, finding reduced potency and breadth compared to pseudotyped viruses.

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.